The SARS-CoV2 pandemic has its implications on the science and art of oncology. The morbidity and mortality associated with SARS-CoV2 are much higher compared to the general population.[1] Data regarding the toxicity of anticancer therapies and their long-term impact are emerging. We have been pushed to a point where we have to weigh the risk–benefit ratio about a particular treatment regimen. To complicate the issue, the world has gone into significant travel restrictions both at the global and local levels. With massive lockdowns affecting multiple countries, there are restrictions on travel at the domestic level and local transport facilities are not available. Hospitals are overburdened with SARS-CoV2 patients, and triaging has taken a front seat in high-volume centers. In a situation like this, many governing bodies have come up with guidelines that cater to the needs and Do's and Don'ts for cancer patients. Here, we apply our collective wisdom and formulate guidelines for treatment recommendations of gastroesophageal cancer that might be applicable for our country where there is a possibility of SARS-CoV2 cases increasing with time.